Literature DB >> 9856957

Chronic nitric oxide inhibition model six years on.

R Zatz1, C Baylis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9856957      PMCID： PMC2745252          DOI： 10.1161/01.hyp.32.6.958

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  103 in total

1.  Evidence that the autonomic nervous system plays a major role in the L-NAME-induced hypertension in conscious rats.

Authors:  R S Cunha; A M Cabral; E C Vasquez
Journal:  Am J Hypertens       Date:  1993-09       Impact factor: 2.689

2.  Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition.

Authors:  D M Pollock; J S Polakowski; B J Divish; T J Opgenorth
Journal:  Hypertension       Date:  1993-05       Impact factor: 10.190

3.  Effect of hypertension induced by nitric oxide synthase inhibition on structure and function of resistance arteries in the rat.

Authors:  L Y Deng; G Thibault; E L Schiffrin
Journal:  Clin Exp Hypertens       Date:  1993-05       Impact factor: 1.749

4.  Selective inhibition of the 12-lipoxygenase pathway of arachidonic acid metabolism by L-arginine or sodium nitroprusside in intact human platelets.

Authors:  M Nakatsuka; Y Osawa
Journal:  Biochem Biophys Res Commun       Date:  1994-05-16       Impact factor: 3.575

5.  Sodium excess aggravates hypertension and renal parenchymal injury in rats with chronic NO inhibition.

Authors:  C K Fujihara; S M Michellazzo; G de Nucci; R Zatz
Journal:  Am J Physiol       Date:  1994-05

6.  Locally produced EDRF controls preglomerular resistance and ultrafiltration coefficient.

Authors:  A Deng; C Baylis
Journal:  Am J Physiol       Date:  1993-02

7.  Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy.

Authors:  J J Morton; E C Beattie; A Speirs; F Gulliver
Journal:  J Hypertens       Date:  1993-10       Impact factor: 4.844

8.  Salt-induced increase in arterial pressure during nitric oxide synthesis inhibition.

Authors:  F J Salazar; A Alberola; J M Pinilla; J C Romero; T Quesada
Journal:  Hypertension       Date:  1993-07       Impact factor: 10.190

9.  Inhibition of nitric oxide synthesis increases blood pressure in healthy humans.

Authors:  W G Haynes; J P Noon; B R Walker; D J Webb
Journal:  J Hypertens       Date:  1993-12       Impact factor: 4.844

10.  Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade.

Authors:  B Jover; A Herizi; F Ventre; M Dupont; A Mimran
Journal:  Hypertension       Date:  1993-06       Impact factor: 10.190
View more
  61 in total

1.  Large BP-dependent and -independent differences in susceptibility to nephropathy after nitric oxide inhibition in Sprague-Dawley rats from two major suppliers.

Authors:  Karen Griffin; Aaron Polichnowski; Hector Licea-Vargas; Maria Picken; Jianrui Long; Geoffrey Williamson; Anil Bidani
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-21

2.  Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat.

Authors:  Aaron Erdely; Gary Freshour; Cheryl Smith; Kevin Engels; Jean L Olson; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2004-03-23

3.  Animal models of regression/progression of kidney disease.

Authors:  Beom Jin Lim; Hai-Chun Yang; Agnes B Fogo
Journal:  Drug Discov Today Dis Models       Date:  2014

Review 4.  Animal models of preeclampsia.

Authors:  Eduardo Podjarny; Gyorgy Losonczy; Chris Baylis
Journal:  Semin Nephrol       Date:  2004-11       Impact factor: 5.299

5.  Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model.

Authors:  Karen A Griffin; Aaron Polichnowski; Natalia Litbarg; Maria Picken; Manjeri A Venkatachalam; Anil K Bidani
Journal:  Hypertension       Date:  2014-06-23       Impact factor: 10.190

6.  Elevated preoperative serum asymmetrical dimethylarginine (ADMA) is associated with poor outcomes after pediatric cardiac surgery.

Authors:  Amanda B Hassinger; Mark S Wainwright; Jerome C Lane; Shannon Haymond; Carl L Backer; Eric Wald
Journal:  Intensive Care Med       Date:  2012-08-09       Impact factor: 17.440

7.  Protection of wistar furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase.

Authors:  Aaron Erdely; Laszlo Wagner; Veronica Muller; Attila Szabo; Chris Baylis
Journal:  J Am Soc Nephrol       Date:  2003-10       Impact factor: 10.121

8.  Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.

Authors:  Amanda E Boe; Mesut Eren; Sheila B Murphy; Christine E Kamide; Atsuhiko Ichimura; David Terry; Danielle McAnally; Layton H Smith; Toshio Miyata; Douglas E Vaughan
Journal:  Circulation       Date:  2013-10-03       Impact factor: 29.690

9.  Vascular Function and Uric Acid-Lowering in Stage 3 CKD.

Authors:  Diana I Jalal; Emily Decker; Loni Perrenoud; Kristen L Nowak; Nina Bispham; Tapan Mehta; Gerard Smits; Zhiying You; Douglas Seals; Michel Chonchol; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2016-09-12       Impact factor: 10.121

10.  Effects of magnesium supplementation on electrophysiological remodeling of cardiac myocytes in L-NAME induced hypertensive rats.

Authors:  Nihal Ozturk; Yusuf Olgar; Mutay Aslan; Semir Ozdemir
Journal:  J Bioenerg Biomembr       Date:  2016-05-18       Impact factor: 2.945
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.